cerulean-pharma-cover-image

Using the science of nanotechnology, Cerulean is developing a suite of potent new cancer drugs that selectively target tumors, burrowing their way into cancer cells while leaving healthy cells unaffected. Clinical results indicate the drugs have the potential to be effective across numerous cancer types, while improving both safety and quality-of-life for patients. The company’s lead drug is currently being evaluated in Phase II clinical trials. The drug platform has also shown promise in delivering gene therapy to cancer cells. The company completed its IPO in 2014.

Nulla adipisicing do ut aliquip elit tempor fugiat. Mollit est exercitation excepteur ea consequat ullamco Lorem ex id. Ipsum nostrud Lorem dolor nisi do est in ex amet eu nostrud. Amet commodo consectetur enim nostrud dolore sint excepteur irure aliqua consectetur. Veniam occaecat et enim eiusmod qui fugiat eiusmod eiusmod laborum exercitation veniam ipsum velit. Ut veniam cupidatat ea tempor ad ad exercitation amet qui. Esse commodo sint deserunt ut elit minim sint. Amet laborum ut adipisicing minim sunt cillum anim in est ipsum aliquip anim in tempor pariatur.

industries

Biology Biochemistry

Advancing Human Health

Milestones

Lux investment: 2007

IPO (NASDAQ: CERU): 2014

Founders

Alan Crane

Ram Sasisekharan

Shiladitya Sengupta

Lux partners
No items found.

Cerulean Pharma

Andrew Wilson
Jasmine Rainey
Tracie Rotter
Stevie Lee
Steven Brody
Shaq Vayda
Shahin Farshchi, PhD
Segolene Scarborough
Sean Traynor
Scott Rubin
Saunaz Moradi
Samuel Arbesman, PhD
Samantha Cho
Peter Hébert
Lindsay Morris
Lan Jiang
Josh Wolfe
Grace Isford
Deena Shakir
Debbie Elsen
Danny Crichton
Dana Riley
Cristina Morris
Chris Gates
Bree Morgan
Brandon Reeves
Brad Gritsch
Bilal Zuberi
Bibi Masara
Alex Nguyen
Adam Kalish